Reverse DCF
What growth does the market imply for AUROPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
conservative
7.3% implied annual FCF growth
The market is pricing in below-GDP growth — very conservative assumption. If the company delivers anywhere near its historical rate, there is significant upside.
Current Price
₹1,376
Historical Growth
18.0%
FCF Yield
5.38%
Price / FCF
18.6x
Plain English
To justify today's price of $1376.00, AUROPHARMA.NS needs to grow its free cash flow at 7.3% per year for the next 10 years. That is 10.7% slower than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 3.6% | ₹1,034 | -24.9% |
| Implied | 7.3% | ₹1,379 | +0.2% |
| GDP rate | 10.0% | ₹1,712 | +24.4% |
| Historical | 18.0% | ₹3,214 | +133.6% |
At Historical Growth Rate
It would take 3 years for AUROPHARMA to organically grow into today's price assuming its historical FCF growth of 18.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.